Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma

Clinical Endocrinology - Tập 76 Số 4 - Trang 586-592 - 2012
Stefanie Dießl1, Barbara Holzberger1, Uwe Mäder2, I. Grelle1, Johannes W. A. Smit3, Andreas K. Buck1, Christoph Reiners1, Frederik A. Verburg1,4
1Department of Nuclear Medicine
2Comprehensive Cancer Center, University of Würzburg, Würzburg, Germany
3Department of Endocrinology, University of Leiden, Leiden, The Netherlands
4Department of Nuclear Medicine, RWTH University Hospital, Aachen, Germany

Tóm tắt

SummaryObjectives  To assess (i) the influence of Thyrotropin (TSH) suppression at a level of <0·1 mU/l and (ii) whether FT3 and FT4 levels have a prognostic significance independently of TSH values with regard to survival in patients with differentiated thyroid carcinoma (DTC) and distant metastases.Patients and methods  In a retrospective patient chart study, we reviewed survival in 157 DTC patients with distant metastases treated between September 1985 and 1 July 2010. Patients with at least three available FT3 and FT4 values during TSH suppression were eligible.Results  Fifty‐three of 157 patients died from DTC. DTC‐specific survival was significantly better in patients with a median TSH level ≤0·1 mU/l (median survival 15·8 years) than those with a non‐suppressed TSH level (median survival 7·1 years; P < 0·001). However, there was no further improvement in survival caused by TSH suppression to a level ≤0·03 mU/l (P = 0·24). FT3 and FT4 levels were also significantly associated with poorer survival; of these, only the prognostic value of FT3 was independent from that of TSH levels.Conclusion  The care of patients with DTC and distant metastases is like walking an endocrinological tightrope: non‐suppressed TSH levels, that is, >0·1 mU/l, are associated with an impaired prognosis. There is, however, no prognostic benefit from suppressing TSH to levels lower than 0·1 mU/l. On the contrary, an improvement in prognosis might be achieved by keeping FT3 levels as low as possible.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM199801293380506

10.1530/EJE-08-0805

10.1111/j.1365-2265.2009.03734.x

Sobin L.H., 2009, TNM Classification of Malignant Tumours

10.1210/jc.2006-2566

10.1507/endocrj.K10E-019

10.1089/thy.2006.16.1229

10.1089/thy.1998.8.737

10.1530/eje.1.02158

10.1210/jc.76.2.494

10.1210/jcem-70-2-453

10.1016/j.yfrne.2007.09.003

10.1016/j.tem.2009.03.011

10.1016/j.jsbmb.2007.12.008

10.1677/ERC-09-0050

Moriggi G., 2011, Thyroid hormones (T3 and T4): dual effect on human cancer cell proliferation, Anticancer Research, 31, 89

10.1111/j.1365-2265.2008.03482.x

10.1111/j.1365-2265.2009.03734.x

10.1007/s00259-009-1315-6

10.1007/s00259-008-0761-x

Sobin L.H., 1997, TNM Classification of Malignant Tumours

Sobin L.H., 2002, TNM Classification of Malignant Tumours

10.1210/jc.2010-0161

10.1002/pros.20725

10.1210/jc.2005-0671

10.1210/jc.2006-0723

Smit J.W., 2005, Reversible diastolic dysfunction after long‐term exogenous subclinical hyperthyroidism: a randomized, placebo‐controlled study, Journal of Clinical Endocrinology and Metabolism, 90, 6041, 10.1210/jc.2005-0620

10.1046/j.1365-2265.1997.d01-1746.x

10.1111/j.1365-2265.1991.tb03509.x

Thông tin
Thông tin xuất bản

Clinical Endocrinology

Tập 76 Số 4

586-592

Thông tin tác giả